Expert Panel: Integrating and Optimizing ADCs in the Treatment of Urothelial Cancer

Antibody-Drug Conjugates: A New Option for Patients With Metastatic Urothelial Carcinoma

Expert Panel: Integrating and Optimizing ADCs in the Treatment of Urothelial Cancer

Minute CME/CE™
Expert Panel: Integrating and Optimizing ADCs in the Treatment of Urothelial Cancer
Media formats available:
Details
Episodes
Documents
  • Overview

    The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use. 
    This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including oncologists, nurses, pharmacists, urologists, dermatologists, and other clinicians involved in managing patients with urothelial cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize the mechanism of action, key components, and potential advantages of antibody-drug conjugates
    • Develop an evidence-based treatment strategy for patients with advanced or metastatic urothelial carcinoma who have progressed on either chemotherapy or a PD-1 or PD-L1 inhibitor
    • Identify and manage adverse events associated with antibody-drug conjugates in patients with advanced or metastatic urothelial carcinoma
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    The following faculty have reported relationships with ineligible companies:

    Petros Grivas, MD, PhD, chair for this educational event, is a contracted researcher for Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck & Co., Mirati Therapeutics, Pfizer, QED Therapeutics; and receives consulting fees from AstraZeneca, Astellas Pharma, Boston Gene, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Guardant Health, Infinity Pharmaceuticals, Janssen, Lucence Health, Merck & Co., Mirati Therapeutics, Pfizer, PureTech, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics, Silverback Therapeutics, 4D Pharma PLC, and UroGen.

    Shilpa Gupta, MD, faculty for this educational event, receives consulting fees from BMS, Pfizer, Merck, Gilead, Bayer, Seattle Genetics, Signetara, Guardant, and Janssen. 

    Vadim S. Koshkin, MD, faculty for this educational event, is a contracted researcher for Endocyte, Nektar, Clovis Oncology, Janssen, Taiho Oncology, and Merck; and receives consulting fees from AstraZeneca, Clovis Oncology, Janssen, Pfizer, EMD Serono, Seagen, Astellas Pharma, Dendreon, Guidepoint, GLG, and ExpertConnect. 

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Megan Reimann, PharmD, BCOP,  planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Astellas, Seagen, and Gilead Sciences, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 11/17/2022 through 11/17/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free